Last reviewed · How we verify

Cifenline — Competitive Intelligence Brief

Cifenline (cibenzoline) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: cibenzoline. Area: Cardiovascular.

marketed cibenzoline ATP-sensitive inward rectifier potassium channel 11, Potassium voltage-gated channel subfamily H member 2, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 Cardiovascular Live · refreshed every 30 min

Target snapshot

Cifenline (cibenzoline).

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Cifenline TARGET cibenzoline marketed cibenzoline ATP-sensitive inward rectifier potassium channel 11, Potassium voltage-gated channel subfamily H member 2, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (cibenzoline class)

  1. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cifenline — Competitive Intelligence Brief. https://druglandscape.com/ci/cibenzoline. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: